[go: up one dir, main page]

MA56513A - Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie - Google Patents

Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie

Info

Publication number
MA56513A
MA56513A MA056513A MA56513A MA56513A MA 56513 A MA56513 A MA 56513A MA 056513 A MA056513 A MA 056513A MA 56513 A MA56513 A MA 56513A MA 56513 A MA56513 A MA 56513A
Authority
MA
Morocco
Prior art keywords
parp14
therapy
protein degradation
targeted protein
targeted
Prior art date
Application number
MA056513A
Other languages
English (en)
Inventor
Kevin Wayne Kuntz
Laurie B Schenkel
Kerren Kalai Swinger
Melissa Marie Vasbinder
Timothy J N Wigle
Original Assignee
Ribon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc filed Critical Ribon Therapeutics Inc
Publication of MA56513A publication Critical patent/MA56513A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA056513A 2019-06-19 2020-06-18 Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie MA56513A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962863357P 2019-06-19 2019-06-19

Publications (1)

Publication Number Publication Date
MA56513A true MA56513A (fr) 2022-04-27

Family

ID=71527971

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056513A MA56513A (fr) 2019-06-19 2020-06-18 Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie

Country Status (11)

Country Link
US (1) US20220388985A1 (fr)
EP (1) EP3986887A1 (fr)
JP (2) JP2022537349A (fr)
KR (1) KR20220024098A (fr)
CN (2) CN114206853A (fr)
AU (1) AU2020296063A1 (fr)
BR (1) BR112021025645A2 (fr)
CA (1) CA3142002A1 (fr)
MA (1) MA56513A (fr)
SG (1) SG11202112980TA (fr)
WO (1) WO2020257416A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20230183T1 (hr) 2017-12-21 2023-05-12 Ribon Therapeutics Inc. Kinazolinoni kao inhibitori parp14
KR20230144008A (ko) * 2021-01-08 2023-10-13 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 님볼리드 유사체 및 이의 사용 방법
US20220265655A1 (en) * 2021-01-29 2022-08-25 Ribon Therapeutics, Inc. Methods of treating inflammatory diseases
CN114890989B (zh) * 2022-05-25 2024-03-22 广东晨康生物科技有限公司 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用
MA71624A (fr) 2022-07-29 2025-05-30 Abbvie Operations Singapore Pte. Ltd. Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie
IL318530A (en) 2022-07-29 2025-03-01 Abbvie Operations Singapore Pte Ltd Targeted protein degradation of PARP14 for use in therapy
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
WO2024251205A1 (fr) * 2023-06-06 2024-12-12 西藏海思科制药有限公司 Dérivé de quinazolinone et son utilisation médicale
CN116813640A (zh) * 2023-06-29 2023-09-29 成都金瑞基业生物科技有限公司 一类抑制并降解parp的化合物及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102438072B1 (ko) * 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
US9505749B2 (en) * 2012-08-29 2016-11-29 Amgen Inc. Quinazolinone compounds and derivatives thereof
KR20240134245A (ko) * 2014-04-23 2024-09-06 인사이트 홀딩스 코포레이션 BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온
WO2017197056A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles
KR20230127371A (ko) * 2016-11-01 2023-08-31 아비나스 오퍼레이션스, 인코포레이티드 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
JP7227912B2 (ja) * 2017-02-08 2023-02-24 ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド キメラ抗原受容体の調節
CA3069181A1 (fr) * 2017-07-12 2019-01-17 Dana-Farber Cancer Institute, Inc. Composes pour la degradation de la proteine tau

Also Published As

Publication number Publication date
WO2020257416A1 (fr) 2020-12-24
JP2022537349A (ja) 2022-08-25
AU2020296063A1 (en) 2021-12-23
BR112021025645A2 (pt) 2022-02-01
US20220388985A1 (en) 2022-12-08
JP2025102917A (ja) 2025-07-08
KR20220024098A (ko) 2022-03-03
EP3986887A1 (fr) 2022-04-27
CN120398840A (zh) 2025-08-01
SG11202112980TA (en) 2021-12-30
CN114206853A (zh) 2022-03-18
CA3142002A1 (fr) 2020-12-24

Similar Documents

Publication Publication Date Title
MA56513A (fr) Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie
IL286462A (en) Protein tyrosine phosphatase inhibitors
MA53921A (fr) Inhibiteurs de protéine tyrosine phosphatase
IL289534A (en) Parp1 inhibitors
DK3681500T3 (da) Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi
EA202091865A1 (ru) Композиции и способы для снижения экспрессии tau
CL2018001724A1 (es) Terapia combinada de inhibidores de proteinas extra-terminales y bromodominio
EP3847249A4 (fr) Expression recombinée d'amine oxydase de fumonisine
DK3532059T3 (da) Kombinationsterapi med bromdomæne- og ekstraterminal proteinhæmmer
DK3737402T5 (da) Modificeret protein
EP3930852A4 (fr) Protéines de liaison à l'antigène se liant à bcma
EP3886912A4 (fr) Dendrimère pour thérapie et imagerie
EP4013440A4 (fr) Peptides thérapeutiques
EP3972610A4 (fr) Thérapie à base de mini-gènes
PL4076380T3 (pl) Przezśluzówkowy system terapeutyczny zawierający agomelatynę
EA201791937A1 (ru) Противовоспалительные полипептиды
IL280706A (en) Non-disruptive mitigation of malware attacks
MA71624A (fr) Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie
EP3976100A4 (fr) Polythérapie
MA55467A (fr) Utilisations thérapeutiques de dulaglutide
MA71618A (fr) Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie
DK3630793T3 (da) Rekombinant protein
EP3603639A4 (fr) Agent thérapeutique ou prophylactique pour neuropathies péripheriques
EP3966567A4 (fr) Peptides thérapeutiques
EP3894546A4 (fr) Utilisations thérapeutiques de fibroblastes génétiquement modifiés